All articles tagged with #neurodegeneration
The youth-associated protein TIMP2 is essential for healthy microglia; its loss ages microglia and impairs debris clearance, while systemic TIMP2 treatment in aged mice reduces inflammation and restores waste-clearing function, suggesting a potential therapeutic pathway for Alzheimer’s and other neurodegenerative diseases.
An unprecedented analysis of over 830,000 brain immune cells from 1,607 donors identified a disease-associated microglia subtype that expands as Alzheimer's progresses and relies on the TREM2-MITF-GPNMB pathway to clear harmful material, suggesting therapies should bolster the brain’s natural immune defenses rather than focus solely on amyloid plaques.
A USC study of about 1,700 adults (average enrollment age ~53) found that those who reported watching TV very often in midlife had smaller memory-related brain regions and broader brain-structure changes two decades later, including smaller frontal and occipital lobes and more white matter damage. These changes persisted after accounting for physical activity and other risk factors; other sedentary activities did not show the same pattern. While observational, the findings suggest what you do while sitting (TV viewing) may influence brain health, and more research is needed to test causation and whether replacing TV time with cognitively engaging activities helps preserve brain health.
Stanford researchers found tau can trigger reverse electron transport in mitochondria, generating reactive oxygen species and cellular stress; blocking this retrograde flow reversed harmful effects and improved learning/memory in flies and mice, suggesting a novel therapeutic angle for Alzheimer’s. Early human cell/tissue data support the idea, and two authors have started a biotech startup to pursue further validation, though results in people remain unproven.
Nature Neuroscience reports a new Alzheimer's pathology: mitochondrial plaques formed from impaired mitophagy, found in both mouse models and human brains, that can appear with or without amyloid-beta, accumulate in neuronal processes, recruit lysosomes, and hamper mitochondrial degradation. This suggests future therapies should target mitochondrial toxicity alongside amyloid pathology and aim to boost mitophagy to slow disease progression.
Researchers show that upregulating the brain protein SORLA in tauopathy mice lowers tau tangles and brain atrophy, preserves synapses and plasticity, and reduces harmful gene activity in glial cells; SORLA deficiency worsens damage, suggesting SORLA as a therapeutic target and hinting that drugs targeting plexin-B receptors could be repurposed for tau-related dementias.
Yale researchers identified two neuron surface proteins, mGluR4 and NPDC1, that help misfolded α-synuclein enter healthy neurons and drive Parkinson's progression; genetically blocking either protein in mice reduced spread and symptoms, pointing to a new therapeutic target to slow the disease.
A Texas A&M study used Theiler's murine encephalomyelitis virus (TMEV) in mice to model Parkinson's-like neurodegeneration. The virus infected dopamine-producing neurons and caused motor deficits that persisted after the virus was cleared, suggesting viruses could contribute to Parkinson's risk alongside genetic or environmental factors. This new viral model offers a tool to study disease progression and etiology, complementing genetic or toxin-based models, though TMEV itself does not infect humans.
Scientists have identified karyoptosis as a key mechanism by which brain cells die in Alzheimer's disease and frontotemporal dementia. The process involves nuclear shrinkage and breakdown triggered by toxic protein buildup; blocking the p38 MAP kinase-LaminB1 interaction in neuron cultures reduced markers of this death pathway, offering a potential new target to slow neuron loss and progression of dementia.
Scientists identify a conserved region (CR; residues 320–340) in TDP-43's low-complexity domain as a drug target. Deleting CR or treating with XL20, a brain-penetrant molecule that binds CR, dampens TDP-43 toxicity, corrects mitochondria-related dysfunction via LLPS, and prolongs survival in ALS mouse models, with positive effects in human mutant TDP-43 motor neurons, all while preserving TDP-43 splicing. XL20 shows CNS penetration and good safety, supporting CR targeting as a therapeutic strategy for TDP-43–related neurodegeneration.
A UCLA-led study found long-term residential exposure to the pesticide chlorpyrifos is linked to more than a 2.5-fold increase in Parkinson’s disease risk. Lab experiments in mice and zebrafish suggest chlorpyrifos damages dopamine neurons by disrupting autophagy, offering insight into the disease mechanism and potential therapeutic targets and underscoring the need for monitoring exposed individuals.
A Salk Institute study reveals that long-term iron buildup in neurons—rather than brief exposure—gradually erodes antioxidant defenses and elevates lipid peroxidation, triggering chronoferroptosis, a time-dependent stress pathway that leaves neurons vulnerable to stress and points to new preventive therapies to combat neurodegenerative diseases.
New research hints that cannabinol, a byproduct of THC, may protect brain cells from oxidative stress and potentially reduce dementia risk, but findings are preliminary and not conclusive; other studies show older adults starting medical cannabis may not experience significant cognitive decline, while concerns about teen use and psychiatric risks persist, leaving the overall impact of cannabis on aging brains unresolved.
ETH Zurich researchers identify inactive GRK2 aggregates that disrupt mitochondrial energy and drive amyloid beta buildup in Alzheimer’s, forming a damaging feedback loop. They developed Compound 10, which blocks GRK2 aggregation, preserves mitochondrial function, reduces amyloid beta, and slows nerve-cell loss in mice, suggesting a new upstream therapeutic approach that could complement existing treatments; a patent has been filed and industry partnerships are being pursued.
UF Health analyzed records from 2012–2024 plus brain tissue and mouse studies and found glucosamine use associated with a 25% higher likelihood of mild cognitive impairment progressing to dementia and a 25% higher mortality in Alzheimer's disease patients. The research points to a hyperactive protein sugar-tagging (glycosylation) pathway as a potential mechanism, suggesting metabolic dysfunction may drive progression, though causality isn’t proven and clinical trials are needed.